Due to the importance of in vitro cytochrome P450 (P450) induction assay to assess the possible drug-drug interaction events, the recent US Food and Drug Administration draft guidance and European Medicines Agency guideline recommend to assess P450 induction using fresh or cryopreserved hepatocytes at mRNA level and/or enzyme activity level. Although cryopreserved hepatocytes are commercially available for P450 induction assays, feasibility and practicability of these hepatocytes have not been fully investigated. In this study, a total of 23 lots of human cryopreserved hepatocytes were treated with three typical inducers (omeprazole, phenobarbital, and rifampicin), and induction of CYP1A2, CYP2B6, and CYP3A4 enzyme activity was measured. In 8 of these 23 hepatocyte lots, induction of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 mRNA was also analyzed. The results revealed that CYP1A2, CYP2B6, and CYP3A4 were induced (>2.0-fold) by omeprazole, phenobarbital, and rifampicin, respectively, in all the hepatocyte lots tested at enzyme activity level (23 lots) and mRNA level (8 lots). In contrast, of the 8 hepatocyte lots treated with rifampicin, CYP2C8 and CYP2C9 mRNA were not induced in 5 and 2 hepatocyte lots, respectively, and CYP2C19 mRNA was not induced in any of the 8 hepatocyte lots tested. These results suggest that induction of CYP1A2, CYP2B6, and CYP3A4 can be readily assessed, but evaluation for CYP2C mRNA induction might not be feasible, using commercially available human cryopreserved hepatocytes.
IntroductionIn vitro P450 induction assays are one of the important experiments in drug discovery and development to assess the potential for drugdrug interaction. The recent Food and Drug Administration (FDA) draft guidance recommends to evaluate induction of CYP1A2, CYP2B6, CYP2C, and CYP3A4 using fresh or cryopreserved hepatocytes by measuring mRNA and/or enzyme activity level (www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362. pdf). A similar recommendation has also been documented in European Medicines Agency (EMA) guidelines (www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2012/07/WC500129606.pdf). One of the major changes from the previous FDA draft guidance is the use of P450 mRNA levels as an endpoint for evaluation of induction. P450 induction has been assessed by measuring enzyme activity; however, mRNA data are also essential to reliably detect test compounds as inducers, which are also mechanism-based inactivators.The FDA draft guidance indicates the use of fresh or cryopreserved hepatocytes in induction assays. Induction of various P450 mRNAs, including CYP1A2, CYP2B6, CYP2C, and CYP3A4 mRNA, has been largely demonstrated mostly using fresh hepatocytes (Raucy et al., 2002;Madan et al., 2003). In contrast, only a limited number of papers has reported such induction results using cryopreserved hepatocytes (Roymans et al., 2005;Hewitt et al., 2007). For P450 induction assays at pharmaceutical companies, the cryopreserved hepato...